TCR

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

Retrieved on: 
월요일, 4월 8, 2024
Public health, Growth, Hematology, Patient, SVP, BMS, Science, Cancer, CRISPR Therapeutics, Baylor College of Medicine, Pleasure, Merrimack Pharmaceuticals, Therapy, Drug development, TCR, Tropical medicine, Pharmaceutical industry

Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization.

Key Points: 
  • Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization.
  • “We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors.
  • “I look forward to working with Chrystal as we strive to realize the full potential of our pipeline.
  • Prior to joining TScan, Dr. Louis was the SVP of hematology clinical development at Zentalis Pharmaceuticals.

Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Retrieved on: 
월요일, 4월 8, 2024
TME, Toxicity, Ovarian cancer, Sarcoma, Tissue, Synovial sarcoma, IND, AACR, Safety, Immune system, Melanoma, TCR, Poster, CSP, Stomach, PD-L1, Vaccine

Impaired T cell functionality and T cell exhaustion are driven by several factors within the hostile solid tumor microenvironment (TME).

Key Points: 
  • Impaired T cell functionality and T cell exhaustion are driven by several factors within the hostile solid tumor microenvironment (TME).
  • This is one major factor that allows cancer cells to proliferate and metastasize without being recognized by the host immune system.
  • Enhanced, gated T cell functionality of CSP-armored rTCR-T cells increased secretion of interferon-γ (IFNγ) only when tumor cells simultaneously expressed the pHLA target antigen and PD-L1.
  • Rapid and sustained killing of 3D tumor cell-derived spheroids only occurred when PD-L1-positive tumor cells simultaneously expressed the specific pHLA target antigen.

Medigene AG Secures European Patent for its iM-TCR Technology

Retrieved on: 
목요일, 4월 4, 2024
TCR, Patent, CSO, Research, Cell death, European Patent Convention, Safety

---  end of press release  ---

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies.
  • “Over the past years we have conscientiously built an extensive international intellectual property portfolio across major markets, which we expect will provide a significant competitive advantage.
  • Each technology we design and develop aims to enhance efficacy and mitigate safety risk to the patient and is based on our extensive immunology research and experience.
  • We are pleased to receive this latest patent grant for our iM-TCR technology from the European Patent Office, which complements our recently granted patent in Japan,” said Dolores Schendel, CSO at Medigene.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
수요일, 4월 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
화요일, 4월 2, 2024
TCR, Patient, Webcast, Conference, Therapy, Cancer

WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.

Key Points: 
  • WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.
  • A webcast of the presentation will be available on the “ Events and Presentations ” section of the Company’s website at ir.tscan.com .
  • An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
목요일, 3월 28, 2024
Research, EUR, Ovarian cancer, Q&A, Partnership, BioNTech, Webcast, Patient, Co-stimulation, G&A, Synovial sarcoma, HLA, AACR, Clinical trial, Therapy, ESMO, Depreciation, Safety, TCR, Patent, Stomach, USD

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.
  • General and administrative (G&A) expenses were EUR 9.3 million in 2023 compared to EUR 7.7 million in the year prior.
  • First pre-clinical data on MDG2011 was presented at the ESMO Congress 2023 and the SITC Annual Meeting 2023.
  • As of Dec 31, 2023, Medigene’s IP portfolio consisted of 112 issued and 131 pending patents across 28 patent families.

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
일요일, 4월 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Toxicity, TP53, Patient, Lung, Arginine, AACR, Cholangiocarcinoma, Therapy, TRAC, Pancreas, CRISPR, TCR, Vaccine

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
  • “We are also proud to present preclinical data from our cell therapy targeting KRAS G12D, which highlights the promising potential of our proprietary non-viral knock-in THRIVE™ platform.
  • The study supports the planned clinical investigation of the novel KRAS G12D mutant TCR-engineered CD4+ and CD8+ T cell therapy in 2024.
  • These data support the planned clinical development of a novel non-viral TRAC-knocked-in T cell therapy for the treatment of p53 R175H-mutant solid tumors.

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
목요일, 3월 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
목요일, 3월 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research

Retrieved on: 
금요일, 4월 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Ovarian cancer, Short interspersed nuclear element, B cell, Fas, SPA, Glomus tumor, MSLN, Neoplasm, Research, RNA, Tumor microenvironment, Abstract, AACR, CA9, Clinical trial, Cancer, CRISPR, Primer, TCR, Engineering, PSMA, Cas9, ICT, Vaccine

Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.

Key Points: 
  • Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.
  • AB-2100 will be studied in a phase 1/2 clinical trial as a potential therapy for clear cell renal cell carcinoma (ccRCC) ( NCT06245915 ).
  • To better characterize CAR induction and receptor turnover, we conducted a series of assays, ultimately demonstrating preclinically that all PrimeR ICT cells have the potential to induce CAR.
  • Leveraging a reductionist in vitro model system, we were also able to analyze CAR induction and receptor turnover.